Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.

NCT01702831 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01702831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01702831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2013
Completion date
July 31, 2022
Enrollment
78 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma